Premium
Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer
Author(s) -
Kristensen Bent,
Mouridsen Henning T.,
Holmegaard Stig N.,
Transbøl Ib
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891101)64:9<1965::aid-cncr2820640933>3.0.co;2-g
Subject(s) - medicine , tamoxifen , primary hyperparathyroidism , antiestrogen , endocrinology , bone remodeling , parathyroid hormone , calcium metabolism , secondary hyperparathyroidism , breast cancer , hyperparathyroidism , cancer , calcium
The effects of adjuvant treatment with tamoxifen on bone metabolism in a postmenopausal woman with primary hyperparathyroidism is presented. A 69‐year‐old woman with increased serum ionized calcium, parathyroid hormone, and 1,25‐(OH)2 vitamin D levels and a normal bone scan received tamoxifen 10 mg three times daily for 1 year. During treatment bone turnover decreased whereas parathyroid hormone increased further. After cessation of treatment the calcium metabolic variables returned to pretreatment levels. The antiestrogen tamoxifen seems to behave as an estrogen on bone metabolism in primary hyperparathyroidism.